Previous 10 | Next 10 |
home / stock / rhhby / rhhby news
Sarepta Therapeutics (NASDAQ: SRPT ) is up 13% premarket on entering into a licensing agreement with Roche ( OTCQX:RHHBY ), providing latter an exclusive commercial rights to SRP-9001, an investigational gene therapy for Duchenne muscular dystrophy (DMD), outside the ...
Deals and Financings Ally Bridge Group, a Hong Kong-New York life science investment firm, announced it has led $140 million of investments in three new medical device companies, bringing its 18-month total to more than $500 million in private life science companies. ABG's latest investments...
It's been tough-going for international investors. A stronger U.S. economy has led to more investment dollars flowing to U.S. equities than foreign companies, resulting in significant under-performance for foreign issues. For instance, the iShares MSCI EAFE ETF ( EFA ) has lagged the SPDR S&am...
As a contrarian investor, I am constantly looking for buying opportunities where the market is irrationally discounting stocks. Empirical research has shown that these contrarian investors on average achieve a high abnormal return. During this research I like to focus on free cash flows, as th...
Exelixis (NASDAQ: EXEL ) inks an agreement with Roche ( OTCQX:RHHBY ) aimed at evaluating the combination of Cabometyx (cabozantinib) and Tecentriq (atezolizumab) for the treatment of patients with locally advanced or metastatic solid tumors. More news on: Exelixis, Inc., Roche Hold...
Arcus Biosciences (NYSE: RCUS ) and Roche ( OTCQX:RHHBY ) will collaborate on two clinical trials, in third-line metastatic colorectal cancer (CRC) and first-line metastatic pancreatic cancer. More news on: Arcus Biosciences, Inc., Roche Holding AG, Bayer Aktiengesellschaft, Healthcare s...
The FDA designates Seattle Genetics' ( SGEN +0.1% ) tucatinib, combined with Roche's ( OTCQX:RHHBY +0.6% ) Herceptin (trastuzumab) and chemo agent capecitabine, a Breakthrough Therapy for the treatment of patients with locally advanced unresectable or metastatic HER2-positive breast ca...
The Trump administration has announced a pilot project allowing states and non-federal government entities to import certain medicines from Canada which pays much lower prices under its single-payer system. More news on: Health Care Select Sect SPDR ETF, SPDR Biotech ETF, Invesco Exchang...
As one of the largest pharma companies out there, I suppose it stands to reason that Roche ( OTCQX:RHHBY ) would have an above-average level of newsflow, but tracking the developments at Roche over the last couple of months has been like trying to sip from a firehose. It’s well worth ...
Listen on the go! A daily podcast of Wall Street Breakfast will be available by 8:00 a.m. on Seeking Alpha , iTunes , Stitcher and Spotify . The crisis at Boeing is deepening after the planemaker halted production of a 737 line for the first time in two decades, as the ...
News, Short Squeeze, Breakout and More Instantly...
Roche Holding Ltd ADR Company Name:
RHHBY Stock Symbol:
OTCMKTS Market:
Wednesday, HOOKIPA Pharma Inc (NASDAQ:HOOK) received clearance from the FDA for its Investigational New Drug (IND) application for H...
– Results from the Phase III study showed that subcutaneous (SC) injection was consistent with IV infusion and demonstrated near-complete suppression of relapse activity (97%) and MRI lesions (97.2%) through 48 weeks – – The twice-yearly, 10-minute SC injection has th...
Monday, Roche Holdings AG (OTC:RHHBY) announced topline data from Phase 3 STARGLO study of Columvi (glofitamab) in combination ...